Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Vor Biopharma Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CAMBRIDGE, MASS., OCT. 03, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT, ON SEPTEMBER 19, 2025, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 76,360 SHARES OF VOR BIO'S COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) REPRESENTING THE RIGHT TO RECEIVE AN AGGREGATE OF 16,361 SHARES OF VOR BIO'S COMMON STOCK TO EIGHT NEWLY HIRED EMPLOYEES. THE FOREGOING STOCK OPTIONS AND RSUS WERE GRANTED AS MATERIAL INDUCEMENTS TO EMPLOYMENT WITH VOR BIO IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WERE GRANTED UNDER THE VOR BIOPHARMA INC. 2023 INDUCEMENT PLAN (THE INDUCEMENT PLAN).

VOR BIO REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

BOSTON, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT CLINICAL DATA FROM THE PHASE 3 STUDY IN CHINA EVALUATING TELITACICEPT IN ADULTS WITH PRIMARY SJGREN'S DISEASE, A STUDY SPONSORED BY VOR'S COLLABORATOR REMEGEN CO., LTD (HKEX: 9995, SHA: 688331), WILL BE PRESENTED AS A LATE-BREAKING POSTER PRESENTATION AT ACR CONVERGENCE 2025, BEING HELD OCTOBER 24-29, 2025, AT MCCORMICK PLACE IN CHICAGO, ILLINOIS.

VOR BIO ANNOUNCES LATE-BREAKING POSTER PRESENTATION OF PHASE 3 PRIMARY SJGREN'S DISEASE CLINICAL STUDY AT ACR CONVERGENCE 2025

CAMBRIDGE, MASS., SEPT. 23, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEDICATED TO TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF NAVID Z.

VOR BIO APPOINTS NAVID Z. KHAN, PH.D.

YANTAI, CHINA , SEPT. 17, 2025 /PRNEWSWIRE/ -- REMEGEN (688331.SH/09995.HK) ANNOUNCED THAT THE 48-WEEK OPEN-LABEL EXTENSION (OLE) DATA FROM CHINA PHASE III CLINICAL STUDY OF TELITACICEPT (RC18, BRAND NAME: , A BLYS/APRIL DUAL-TARGET FUSION PROTEIN INNOVATIVE DRUG INDEPENDENTLY DEVELOPED BY REMEGEN) FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) WAS SELECTED AS AN ORAL PRESENTATION AT THE 2025 AMERICAN ASSOCIATION OF NEUROMUSCULAR & ELECTRODIAGNOSTIC MEDICINE (AANEM) ANNUAL MEETING.

RESULTS OF CHINA PHASE III CLINICAL STUDY OF TELITACICEPT FOR GENERALIZED MYASTHENIA GRAVIS SELECTED FOR ORAL PRESENTATION AT 2025 AANEM ANNUAL MEETING

CAMBRIDGE, MASS., SEPT. 17, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT 48-WEEK CLINICAL DATA FROM THE PHASE 3 STUDY IN CHINA EVALUATING TELITACICEPT IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS, A STUDY SPONSORED BY VOR'S COLLABORATOR REMEGEN CO., LTD (HKEX: 9995, SHA: 688331), WILL BE PRESENTED AS AN ORAL PRESENTATION AT THE AMERICAN ASSOCIATION OF NEUROMUSCULAR & ELECTRODIAGNOSTIC MEDICINE ANNUAL MEETING, BEING HELD OCTOBER 29 TO NOVEMBER 1, 2025, AT THE HILTON SAN FRANCISCO UNION SQUARE IN SAN FRANCISCO, CALIFORNIA.

VOR BIO ANNOUNCES ORAL PRESENTATION OF 48-WEEK CHINA PHASE 3 GENERALIZED MYASTHENIA GRAVIS CLINICAL STUDY AT AANEM

CAMBRIDGE, MASS., SEPT. 12, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN A FIRESIDE CHAT AND HOST VIRTUAL 1X1 INVESTOR MEETINGS AT THE STIFEL 2025 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM.

VOR BIO TO PARTICIPATE IN THE STIFEL2025 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM

CAMBRIDGE, MASS., SEPT. 02, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF ADI OSOVSKY, S.J.D.

VOR BIO APPOINTS ADI OSOVSKY, S.J.D. AS GENERAL COUNSEL

CAMBRIDGE, MASS., AUG. 26, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: CITI'S 2025 BIOPHARMA BACK TO SCHOOL CONFERENCE FIRESIDE CHAT: TUESDAY, SEPTEMBER 2ND, 2025, AT 11:15AM ETLOCATION: BOSTON, MA A LIVE WEBCAST AND ARCHIVED REPLAY OF THE FIRESIDE CHAT WILL BE AVAILABLE ON THE INVESTORS SECTION OF WWW.VORBIO.COM.

VOR BIO TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

CAMBRIDGE, MASS., AUG. 18, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT, BETWEEN AUGUST 4, 2025, AND AUGUST 18, 2025, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS GRANTED STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 6,959,013 SHARES OF VOR BIO'S COMMON STOCK AND RESTRICTED STOCK UNITS (RSUS) REPRESENTING THE RIGHT TO RECEIVE AN AGGREGATE OF 1,491,217 SHARES OF VOR BIO'S COMMON STOCK TO SEVEN NEWLY HIRED EMPLOYEES. THE FOREGOING STOCK OPTIONS AND RSUS WERE GRANTED AS MATERIAL INDUCEMENTS TO EMPLOYMENT WITH VOR BIO IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WERE GRANTED UNDER THE VOR BIOPHARMA INC. 2023 INDUCEMENT PLAN (THE INDUCEMENT PLAN).

PHASE 3 RESULTS POSITION TELITACICEPT AS POTENTIAL BEST-IN-DISEASE PROFILE IN PRIMARY SJGREN'S DISEASE TELITACICEPT DEMONSTRATED A FAVORABLE SAFETY PROFILE VOR EVALUATING TIMING OF GLOBAL PHASE 3 CLINICAL STUDY IN PRIMARY SJGREN'S DISEASE DATA ANTICIPATED TO BE PRESENTED AT AN UPCOMING MEDICAL CONFERENCE CAMBRIDGE, MASS., AUG. 13, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT ITS COLLABORATOR, REMEGEN CO., LTD (HKEX: 9995, SHA: 688331), ACHIEVED THE PRIMARY ENDPOINT IN A PHASE 3 CLINICAL STUDY IN CHINA EVALUATING TELITACICEPT IN ADULTS WITH PRIMARY SJGREN'S DISEASE.

Vor Biopharma Inc.

VOR

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Vor Biopharma Inc.

VOR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

VOR